AI-Generated Summary
This post outlines five key strategies for pharmacists to enhance the management of acute uncomplicated cystitis by emphasizing accurate, symptom-based diagnosis, using local resistance data to guide empiric antibiotic choices, and interpreting urine cultures appropriately. It also highlights the importance of distinguishing colonization from infection in older adults and providing targeted patient counseling to reduce recurrence and unnecessary antibiotic use.
Authored By: Saeed Aldosari, PharmD, BCPS, BCIDP
Article posted 7 January 2026
Urinary tract infections (UTIs) are among the most common outpatient infections encountered in the United States, with a lifetime incidence of 50–60% in adult women. They account for approximately 7 million medical visits annually. With such a high frequency of occurrence, pharmacists are often engaged in supporting optimal management of UTIs to optimize clinical and economic outcomes. This may occur directly in antimicrobial stewardship programs or through routine work. Pharmacists council patients, review cultures, recommend guideline-directed therapies, and more.
The Infectious Diseases Society of America guidelines address acute uncomplicated UTI in non-premenopausal, non-pregnant women with no known urological abnormalities or comorbidities. They characterize it by symptoms such as dysuria, frequency, and urgency, without evidence of complications like pyelonephritis or systemic infection. This will also be the focus for this article. Effective UTI management requires integrating diagnostic criteria, microbiology interpretation, resistance data, and patient counseling into clinical practice.
The goal of this article is to identify and discuss five tips for pharmacists to consider which may help improve acute uncomplicated UTI management.
TIP 1. Start with the fundamentals – get a full clinical picture
Abnormalities on urinalysis (including pyuria/ presence of WBCs) alone cannot establish a diagnosis of uncomplicated cystitis. Compatible symptoms such as dysuria, frequency and urgency must also be present. Pyuria is common in patients with asymptomatic bacteriuria (i.e., a positive urine culture with no symptoms). This often reflects inflammation rather than an active infection that requires treatment. Beware that both pyuria and asymptomatic bacteriuria are very common in patients with chronic urinary catheters. So if we just react to positive labs and do not correlate findings to patient symptoms, we can end up giving inappropriate antibiotics.
Changes in urine color, clarity, or odor are also non-specific and cannot independently diagnose cystitis that requires antibiotic therapy. For example, having asparagus for dinner may change the odor of urine, but it certainly does not indicate a UTI!
Clinical Case example: An older adult with a positive urine culture along with cloudy, foul-smelling urine and pyuria on urinalysis. They are not found to havedysuria, urgency, suprapubic pain, or fever. This patient meets criteria for asymptomatic bacteriuria. Treatment of asymptomatic bacteriuria in non-pregnant adults does not improve clinical outcomes and increases the risk of antimicrobial resistance as well as adverse drug events. Pharmacists should reinforce symptom-based diagnostic criteria and discourage antibiotic initiation based solely on urinalysis findings. It may be particularly helpful to leverage local treatment guidelines when discussing recommendations to patients, care givers, or clinicians about rational UTI management. Patients may also benefit from education regarding what constitutes a true infection, which may be contrary to their base assumptions.
TIP 2. Tap into local antibiotic resistance data to guide empiric therapy decisions
Empiric therapy (i.e., initial antibiotic before final cultures and susceptibilities) for acute uncomplicated cystitis should be guided by local susceptibility data whenever possible, rather than national averages or historical practice patterns. Cumulative antibiograms can support this.
Nitrofurantoin is a go-to drug for this indication and often demonstrates higher susceptibility rates than trimethoprim-sulfamethoxazole or fluoroquinolones against E. coli in many regions of the US. Rising antimicrobial resistance contributes to the increasing burden of UTIs.
Extended-spectrum beta-lactamase producing Enterobacterales are of particular concern across the United States. We can observe ceftriaxone resistance among urinary E. coli isolates as an ESBL rate marker. Reviewing this type of cumulative data over multiple years can give valuable perspective on changes that are occurring in the local community. When resistance or limited options exist, oral fosfomycin may also be considered as an option.
From a pharmacist perspective, reviewing patient-specific microbiology and risk factors is critical. Contextualizing individual risk is more valuable than making assumptions off of cumulative antibiograms.
Recently approved oral agents such as gepotidacin (FDA-approved March 2025), sulopenem (FDA-approved October 2024), and pivmecillinam (FDA-approved April 2024) are expand the antimicrobial landscape for acute uncomplicated cystitis. They may be particularly useful in the setting of drug resistance, allergies, or other complicating factors. However, the optimal role of these agents remains to be determined and cost as well as confirming susceptibilities is a likely barrier to use.
TIP 3. Interpret urine microbiology results with a structured, actionable approach
Unnecessary urine testing contributes to antibiotic overuse across healthcare settings. Positive urine cultures should be interpreted in the context of documented urinary symptoms rather than in isolation.
Pharmacists can apply a structured framework when reviewing urine microbiology results by confirming symptom presence, evaluating whether the isolated organism plausibly explains the presentation, and assessing colony counts and culture quality. Mixed flora or low colony counts are more consistent with contamination than infection and generally do not warrant treatment. Clear-cut indications for treatment include symptomatic patients with compatible organisms, whereas positive cultures without symptoms represent asymptomatic bacteriuria and should not prompt therapy.
Pharmacists can also educate other team members such as nurses about proper UTI diagnosis. For example if someone blindly calls a positive urine culture a UTI, that may be a great time to educate on the fallacies of treating labs rather than patients.
TIP 4. Recognize colonization versus infection in older adults
Asymptomatic bacteriuria is common among older adults, particularly those in long-term care facilities. In this population, bacteriuria often persists despite antibiotic therapy and does not represent an infection requiring treatment. Antibiotic treatment of colonization increases the risk of Clostridioides difficile infection and antimicrobial resistance without improving patient outcomes.
Pharmacists should be especially cautious when urine testing is performed for non-specific symptoms such as altered mental status, as these findings alone do not establish a diagnosis of UTI. Reframing positive cultures as colonization rather than infection helps prevent unnecessary antibiotic exposure and aligns care with guideline recommendations.
Understanding the particular nuances of each patient population may help support pharmacists being more effective in their engagement in UTI management.
TIP 5. Provide targeted patient counseling to reduce recurrence risk
Recurrent uncomplicated UTIs affect a significant proportion of women and contribute to repeated antibiotic exposure. Patient education is a cornerstone of recurrence prevention and should be consistently reinforced by pharmacists.
–General counseling pearls include:
- Completing the full prescribed antibiotic course unless advised otherwise by a provider
- Maintaining adequate hydration by drinking 2-3 liters of fluid daily to help flush bacteria from the urinary tract
- Voiding immediately after sexual intercourse to reduce bacterial introduction
- Considering cranberry products if desired, though evidence is mixed and they should not replace proven strategies
–Drug-specific counseling pearls include:
- Nitrofurantoin should not be used for suspected pyelonephritis due to inadequate renal tissue penetration. Avoid it if creatinine clearance is less than 30 mL/min due to reduced efficacy and increased toxicity risk. Take with food to minimize gastrointestinal upset.
- TMP-SMX requires attention to drug interactions (e.g., with warfarin) and adverse effects such as rash or hyperkalemia. Avoid if sulfa allergy is present.
- Oral fosfomycin is administered as a single 3-gram dose mixed with 3-4 ounces of water. Symptom resolution may be delayed up to 48 hours.2
Closing Comments
UTIs including acute uncomplicated cystitis represent a common clinical problem with substantial implications for antimicrobial resistance1 Pharmacists play a central role in improving UTI management by supporting accurate diagnosis, guiding empiric therapy using resistance data, interpreting microbiology results appropriately, and providing effective patient counseling. Applying these principles in everyday practice can significantly reduce unnecessary antibiotic use, improve patient outcomes, and support the health of your community.
References:
1. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019;11:1756287219832172. doi:10.1177/1756287219832172
2. Gupta K, Hooton TM, Naber KG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257
3. Anger J, Lee U, Ackerman AL, et al. Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol. Published online August 2019. doi:10.1097/JU.0000000000000296
4. Beahm NP, Smyth DJ, Tsuyuki RT. Antimicrobial utilization and stewardship in patients with uncomplicated urinary tract infections managed by pharmacists in the community: A sub-study of the RxOUTMAP trial. J Assoc Med Microbiol Infect Dis Can. 6(3):205-212. doi:10.3138/jammi-2020-0047
5. Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of Americaa. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121
6. Schulz L, Hoffman RJ, Pothof J, Fox B. Top Ten Myths Regarding the Diagnosis and Treatment of Urinary Tract Infections. J Emerg Med. 2016;51(1):25-30. doi:10.1016/j.jemermed.2016.02.009
7. IDSA. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. Accessed December 18, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/
8. Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Aging Health. 2013;9(5):10.2217/ahe.13.38. doi:10.2217/ahe.13.38
About the Author
Saeed Aldosari, Pharm.D., BCPS, BCIDP is an Infectious Diseases Pharmacist and Health Outcomes Fellow at Nova Southeastern University College of Pharmacy. He completed residency training (PGY-1, PGY-2 Infectious Diseases) at Tufts Medicine Melrose Wakefield Hospital. He holds board of pharmacy certifications in pharmacotherapy and infectious diseases.
His research interests include antimicrobial stewardship, resistance modeling, diagnostic stewardship, and treatment outcomes. He has experience in clinical practice, teaching, and inter-professional education. He has a strong commitment to optimizing patient care through evidence-based pharmacotherapy, innovative research, and academic collaboration.
Recommended To You
